Results 221 to 230 of about 6,836,441 (345)

Comprehensive profiling of lncRNAs and mRNAs enriched in small extracellular vesicles for early noninvasive detection of colorectal cancer: diagnostic panel assembly and extensive validation

Molecular Oncology, EarlyView.
Small extracellular vesicles are a promising source of diagnostic molecules. We conducted a comprehensive study, including transcriptome profiling and RT‐qPCR validation on large cohorts of samples. Diagnostic panels enabling sensitive detection of colorectal cancer and precancerous lesions were established. Some molecules were differentially expressed
Petra Vychytilova‐Faltejskova, Marketa Pavlikova, Lucie Pifkova, Robin Jugas, Tana Machackova, Lenka Radova, Milana Sachlova, Renata Bartosova, Tetiana Samoilenko, Zuzana Feckova, Jana Orlickova, Erika Slamova, Elleni Ponechal Michu, Dagmar Al Tukmachi, Michaela Ruckova, Martina Vodinska, Jan Kotoucek, Tina Catela Ivkovic, Marie Boudna, Lucia Bohovicova, Teodor Stanek, Jana Halamkova, Martin Svoboda, Vladimir Prochazka, Tomas Grolich, Zdenek Kala, Ondrej Slaby   +26 more
wiley   +1 more source

Patient-Reported Outcomes for Patients With Metastatic NSCLC Treated at an Academic Medical Center, 2017-2021. [PDF]

Cancer Med
Williams LA, Xu C, Ponce DA, Shi Q, Santorelli ML, Burke T, Altan M.   +6 more
europepmc   +1 more source

PMD18 REAL-LIFE PATIENT REPORTED OUTCOMES: DATA MINING OF CONSUMER SPONTANEOUS REPORTS FOR TWO STATINS

, 2004
MW Reynolds, Steven J. Ross, K Fahrbach, David Frame, Katherine M. James   +4 more
openalex   +1 more source

The critical role of DNA damage‐inducible transcript 4 (DDIT4) in stemness character of leukemia cells and leukemia initiation

Molecular Oncology, EarlyView.
Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li, Zhijie Cao, Haiyan Xing, Zhenya Xue, Wenbing Liu, Jiayuan Chen, Yihan Mei, Runxia Gu, Hui Wei, Shaowei Qiu, Min Wang, Qing Rao, Jianxiang Wang   +12 more
wiley   +1 more source

Symptoms, side effects, quality of life and financial toxicity matter to patients with cancer, we need to do a better job of capturing and reporting these concepts in trials and clinical care

BMJ Oncology
Melanie Calvert, Roger Wilson, John Devin Peipert   +2 more
doaj   +1 more source

PAR7 ASSESSMENT OF PATIENT-REPORTED OUTCOMES AMONG OSTEOARTHRITIC PATIENTS

, 2004
SR Gandra, LW Lawrence
openalex   +1 more source

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial [PDF]

, 2006
Dafna D. Gladman, Philip J. Mease, M. Cifaldi, Renee Perdok, Eric H. Sasso, J Medich   +5 more
openalex   +1 more source

Patient‐reported outcomes (PROs) versus patient‐reported outcome measures (PROMs)—Is there a difference? [PDF]

Clinical and Experimental Dental Research, 2018
openaire   +3 more sources

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance [PDF]

, 2006

openalex   +1 more source